PCOS Has a New Name: PMOS. Here Is What It Means — And What Shatavari, Ashwagandha and 2026 Science Say About Managing It Naturally

By Kuerzen Research Team | Kuerzen BioSolutions Pvt. Ltd. | FSSAI Certified

On 12 May 2026, The Lancet published a landmark global consensus renaming Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome — PMOS. The change followed 14 years of collaboration across 56 leading academic, clinical, and patient organisations, with input from over 14,300 patients and healthcare professionals worldwide. The renaming is not cosmetic. It officially recognises what millions of Indian women already knew: this condition is far bigger than ovaries, far more complex than cysts, and far more deserving of a complete, multi-system approach than conventional medicine has historically offered.

If you have been told you have PCOS — now officially renamed PMOS — you are not alone and you are not broken. This is the most common hormonal disorder among Indian women of reproductive age, affecting an estimated one in five. What makes it so difficult to manage is that it operates through four interconnected biological pathways simultaneously — hormonal imbalance, insulin resistance, chronic inflammation, and adrenal stress. Most conventional treatments address only one. What 2026 clinical research now confirms is that certain Ayurvedic botanicals, standardised to meaningful doses, may address multiple pathways at once. India has known about these plants for three thousand years. Science is now catching up.

Why PCOS Has Been Renamed PMOS — And Why It Matters for You

For decades, the term Polycystic Ovary Syndrome misled both patients and doctors. The name implied the presence of pathological ovarian cysts — which are not actually a feature of the condition. What appears on ultrasound are arrested follicles, not cysts. This mischaracterisation led to significant diagnostic delays affecting up to 70% of those with the condition, fragmented care, stigma, and missed opportunities for early intervention in metabolic and cardiovascular risks.

The new name — Polyendocrine Metabolic Ovarian Syndrome — officially recognises the four pathways that have always driven this condition. The "polyendocrine" prefix acknowledges multiple interacting hormonal disturbances including insulin, androgens, and neuroendocrine hormones. The "metabolic" component acknowledges insulin resistance and cardiometabolic risk. This is the scientific validation of what Ayurvedic practitioners observed three thousand years ago — and what the clinical research on Shatavari and Ashwagandha now confirms. The renaming also means clinical guidelines, medical education, and international disease classification systems will now be updated to reflect this multi-system reality — which will change how millions of Indian women are diagnosed and treated going forward.

Why PCOS (now PMOS) Is So Hard to Treat — The Four Pathways

PCOS (now PMOS) has no single cause and no single solution. It operates through four interconnected biological pathways. Most conventional treatments address only one pathway at a time — which is why they often do not work well enough.

PCOS (now PMOS) disrupts your body through four connected roads: hormonal imbalance causing irregular periods and acne, insulin resistance driving weight gain and fatigue, chronic inflammation leading to body aches and mood issues, and adrenal stress making everything worse when you are anxious. Most treatments fix only one. That is why they fall short.

Key fact: Approximately 70% of women with PCOS (now PMOS) have insulin resistance, making it a metabolic condition as much as a reproductive one — which is precisely why the medical community chose to rename it.

The Three Clinically Proven Herbs for PCOS (now PMOS)

1. Shatavari — The 2026 Clinical Breakthrough

Shatavari (Asparagus racemosus) has been used in Ayurveda for over three thousand years as the primary herb for women's reproductive health. Its name translates to "she who possesses a hundred husbands" — a reference to its traditional role in supporting female vitality and fertility.

The 2026 RCT Evidence

A randomised, double-blind, placebo-controlled trial — the gold standard in clinical research — was published in Frontiers in Endocrinology (Mhatre et al., 2026). The trial enrolled 70 women aged 20–40 with confirmed PCOS (now PMOS), randomised to either standardised Shatavari root extract or placebo for 12 weeks. The results were clinically significant across all four measured parameters. Ovarian volume reduced by 26.4% (from 12.5 mL to 9.2 mL), follicle count reduced by 31.0% (from 14.2 to 9.8), insulin sensitivity improved by 23.7% (HOMA-IR from 3.8 to 2.9), and total testosterone reduced by 23.5% (from 68 ng/dL to 52 ng/dL). All improvements were statistically significant at p<0.01 compared to placebo.

A separate 2026 study in the International Journal of Women's Health (Ademola et al., 2026) found that Shatavari also significantly improved fatigue, sleep quality, mood swings, and anxiety — outcomes rarely addressed by conventional PCOS (now PMOS) treatments.

The customer truth: If your periods are irregular and energy is low, Shatavari targets the hormonal pathway most PCOS (now PMOS) treatments miss.

2. Ashwagandha — The Cortisol and Stress Specialist

Ashwagandha (Withania somnifera) is classified in Ayurveda as a rasayana — a rejuvenating tonic — and is one of the most extensively studied adaptogens in modern pharmacology. Its relevance to PCOS (now PMOS) is specific and mechanistically grounded.

Clinical Evidence for Cortisol Reduction

A clinical study published in the Indian Journal of Psychological Medicine (Chandrasekhar et al., 2012) demonstrated a 27.9% reduction in serum cortisol following eight weeks of KSM-66 Ashwagandha supplementation — a clinically significant reduction that would meaningfully reduce adrenal androgen stimulation in women with PCOS (now PMOS). A systematic review in Medicine (Pratte et al., 2014) confirmed that standardised Ashwagandha extract significantly reduces serum cortisol, self-reported stress scores, and anxiety in adults with chronic stress.

Anti-Inflammatory Effects

Beyond cortisol reduction, Ashwagandha demonstrates direct anti-inflammatory effects through inhibition of NF-kB signalling pathways — one of the primary inflammatory cascades elevated in PCOS (now PMOS).

The customer truth: If your PCOS (now PMOS) symptoms flare up during stressful weeks — more acne, heavier cycles, more fatigue — Ashwagandha targets that exact stress-hormone link.

3. Flaxseed — Insulin Sensitivity and Anti-Inflammatory

Flaxseed (Linum usitatissimum) is rich in lignans — phytoestrogens that modulate oestrogen metabolism and improve insulin sensitivity — and omega-3 fatty acids (ALA) that directly reduce inflammatory markers CRP and IL-6. A randomised controlled trial found that 30g per day of flaxseed reduced hyperandrogenism and improved menstrual regularity in women with PCOS (now PMOS) (Nowak et al., Journal of the American College of Nutrition, 2016). Its lignans improve insulin sensitivity, its omega-3 fatty acids reduce inflammation, and its phytoestrogenic compounds support hormone balance — covering two of the four PCOS (now PMOS) pathways that Shatavari and Ashwagandha do not fully address alone.

The customer truth: Flaxseed addresses both insulin resistance and inflammation — two pathways that Shatavari and Ashwagandha do not fully cover alone.

Complete Super Her Ingredient Breakdown

Super Her is not just a botanical blend. It is a complete plant-based protein, fibre, enzyme, adaptogen, and micronutrient formulation designed specifically for Indian women with PCOS (now PMOS).

Ingredient	Dose per 24g scoop	PCOS (now PMOS) Role
Pea + Brown Rice Protein Isolate	15g protein	Low-glycaemic, dairy-free satiety
Soluble Dextrin Fibre	Proprietary	Improves insulin sensitivity
Digestive Enzymes (Protease, Peptidase, Amylase, Lactase)	Proprietary	Reduces bloating, improves absorption
Vitamin C	Proprietary	Antioxidant + enhances iron absorption
Shatavari	Clinical dose	Hormonal regulation (2026 RCT)
Ashwagandha KSM-66	Clinical dose	27.9% cortisol reduction
Spirulina	500mg	Iron, B12, phycocyanin antioxidant
Flaxseed	Proprietary	Insulin sensitivity + anti-inflammatory
Alfalfa	Proprietary	Phytoestrogens + liver detox support
Cocoa Powder + Stevia	Proprietary	Natural sweetness, zero glycaemic impact

How Super Her Addresses All Four PCOS (now PMOS) Pathways

Super Her does not pick one pathway. It covers all four simultaneously. Hormonal balance is addressed through Shatavari and Alfalfa. Insulin resistance is addressed through plant protein, soluble fibre, and flaxseed. Inflammation is addressed through Ashwagandha, Spirulina, and Vitamin C. And adrenal stress is addressed through Ashwagandha KSM-66, which delivers a clinically proven 27.9% cortisol reduction. This is not a product designed around marketing trends. It is a product designed around the same multi-system understanding of PCOS (now PMOS) that The Lancet has now officially endorsed.

Why Indian Women with PCOS (now PMOS) Need This Complete Approach

Over 50% of Indian women are iron deficient (NFHS-5, 2019–21). Most vegetarians lack B12. PCOS (now PMOS) makes both worse — the condition's hormonal disruptions compound existing nutritional deficiencies, creating a cycle that no single ingredient can break. Super Her fills these gaps with Spirulina and Vitamin C — no separate pills needed. A complete formulation addresses all of them at once, which is precisely what a multi-system condition demands.

What Can Help?

For Indian women looking for daily nutritional support that addresses PCOS (now PMOS) from multiple angles, Kuerzen's Super Her is formulated specifically with this complexity in mind. Super Her combines Shatavari and Ashwagandha KSM-66 — both present at clinically meaningful doses — alongside Flaxseed, Spirulina, Vitamin B6, and Vitamin C to address the micronutrient deficiencies that are universal among Indian women with PCOS (now PMOS). Every ingredient is chosen not for label appeal but for its specific, evidence-based role in the multi-pathway management of hormonal imbalance, insulin sensitivity, inflammation, and adrenal stress.

Super Her is FSSAI-certified, GMP-manufactured at Kuerzen Biosolutions Pvt. Ltd. in Greater Noida, and developed by a pharmaceutical team with over 20 years of clinical research experience. It is not a treatment for PCOS (now PMOS) — no supplement is — but it is formulated to support the biological processes that PCOS (now PMOS) disrupts, at doses that clinical research validates as effective. For Indian women navigating PCOS (now PMOS) in a system that rarely offers complete answers, Super Her represents the kind of complete nutritional support that the condition's complexity demands.

Frequently Asked Questions

What is PMOS and how is it different from PCOS?

PMOS — Polyendocrine Metabolic Ovarian Syndrome — is the new official name for what was previously called PCOS, published in The Lancet on 12 May 2026. The name change reflects decades of scientific evidence showing that the condition is not primarily about ovarian cysts — many women with PCOS (now PMOS) do not have visible cysts at all — but is instead a complex, multi-system hormonal and metabolic condition. The renaming is intended to reduce the diagnostic delays and fragmented care that the old name contributed to, and to ensure that the metabolic and endocrine dimensions of the condition receive the medical attention they require.

Why plant protein instead of whey for PCOS and PMOS?

Whey can worsen acne and bloating in some women with PCOS (now PMOS) due to lactose content and IGF-1 stimulation. Pea and brown rice protein is hypoallergenic, low-glycaemic, and hormone-free — making it a more appropriate protein source for women managing PCOS (now PMOS) symptoms alongside their nutritional goals.

Can Shatavari help with PCOS and PMOS?

Emerging clinical evidence, including a 2026 randomised controlled trial published in Frontiers in Endocrinology, suggests that standardised Shatavari root extract may support multiple aspects of PCOS (now PMOS) management — including improving ovarian morphology, insulin sensitivity, androgen balance, and menstrual regularity. It is not a treatment for PCOS (now PMOS) and should not replace medical care, but the evidence for its supportive role is now grounded in gold-standard clinical research. The key is ensuring the Shatavari is present at a meaningful standardised dose — not a trace amount included for label purposes.

What do the digestive enzymes in Super Her do?

They reduce bloating, improve protein absorption, and help digest lactose if accidentally consumed — a common hidden contributor to digestive discomfort in women with PCOS (now PMOS) who may have undiagnosed lactose sensitivity.

How long before I see results from Shatavari and Ashwagandha?

Energy and mood improvements are typically noticed within 4–6 weeks of consistent daily use. Menstrual regularity improvements generally emerge over an 8–12 week period, which aligns with the 12-week intervention period used in the 2026 clinical trial. Consistency is essential — these botanicals work through gradual normalisation of biological pathways, not as acute interventions.

Does PCOS or PMOS go away on its own?

PCOS (now PMOS) does not resolve without intervention, but its symptoms can improve significantly with the right combination of dietary changes, physical activity, stress management, and multi-ingredient nutritional support. The goal of management is not elimination of PCOS (now PMOS) but reduction of its impact on daily quality of life, hormonal health, and long-term metabolic risk.

The Bottom Line

PCOS (now PMOS) is not a sentence. It is a signal — that your hormones, metabolism, inflammation, digestion, and stress systems are out of balance. The Lancet's renaming of PCOS to PMOS on 12 May 2026 has officially confirmed what millions of Indian women already knew: this condition is far bigger than ovaries, far more complex than cysts, and far more deserving of a complete, multi-system approach than conventional medicine has historically offered.

You deserve an approach that takes all four pathways seriously — not just the easiest one to treat. Super Her is a complete plant-based protein formulation designed specifically for Indian women with PCOS (now PMOS). It delivers 15g of plant protein from pea and brown rice — dairy-free and low-glycaemic — alongside soluble fibre for insulin sensitivity, digestive enzymes to eliminate bloating, and the complete botanical complex of Shatavari, Ashwagandha KSM-66, Flaxseed, Spirulina, Alfalfa, and Vitamin C that collectively addresses all four PCOS (now PMOS) pathways. Naturally sweetened with cocoa and stevia — zero artificial sweeteners, zero glycaemic impact.

Ancient wisdom. 2026 clinical science. India-specific nutrition. Digestive support. All in one serving.

For more information, visit kuerzen.com

Key References

[1] Mhatre Y et al. Efficacy and safety of Shatavari root extract in women with PCOS (now PMOS). Frontiers in Endocrinology. 2026. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1769773/full

[2] Ademola J et al. Effects of Shatavari on women's wellness. International Journal of Women's Health. 2026. https://doi.org/10.2147/IJWH.S561213

[3] Chandrasekhar K et al. Ashwagandha and cortisol reduction. Indian Journal of Psychological Medicine. 2012. https://pubmed.ncbi.nlm.nih.gov/23439798/

[4] Pratte MA et al. Ashwagandha systematic review. Medicine. 2014. https://pubmed.ncbi.nlm.nih.gov/25405876/

[5] Nowak DA et al. Flaxseed in PCOS (now PMOS). Journal of the American College of Nutrition. 2016. https://pubmed.ncbi.nlm.nih.gov/25603503/

[6] Calella P et al. Spirulina and recovery. Frontiers in Nutrition. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9795056/

[7] NFHS-5. National Family Health Survey India 2019–21. http://rchiips.org/nfhs/NFHS-5Reports/NFHS-5_INDIA_REPORT.pdf

[8] JHRS. PCOS (now PMOS) prevalence India. https://pubmed.ncbi.nlm.nih.gov/22355229/

[9] USDA FoodData Central. Spirulina nutrition. https://fdc.nal.usda.gov/fdc-app.html#/food-details/170495/nutrients

[10] Teede HJ et al. Polyendocrine metabolic ovarian syndrome: global consensus renaming. The Lancet. May 12, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00503-X/fulltext